Anthony Lam, MD
Internal Medicine · Tustin, CANPI 1659502839
Payments from drug & device makers
Across 643 payments — averaging $414.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$136K
- Bayer$67K
- Janssen Research & Development, LLC$38K
- Boehringer Ingelheim International GmbH$4K
- Boehringer Ingelheim Pharma GmbH & Co.kg$4K
- Spectrum Pharmaceuticals Inc.$3K
- plus $13K from 49 others
What the payments were for
- Consulting fees$17,16121%
- Speaking & faculty fees$41,50952%
- Travel & lodging$6,6898%
- Food & beverage$14,14618%
- Education$9921%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$266,691 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 61 | $894,781 |
| NubeqaDarolutamide | 37 | $496,424 |
| OrgovyxRelugolix | 98 | $258,719 |
| CabometyxCabozantinib S-Malate | 15 | $243,990 |
| Lenalidomide | 11 | $109,712 |
| Imatinib Mesylate | 12 | $57,357 |
| Lupron DepotLeuprolide Acetate | 11 | $42,773 |
| Anastrozole | 70 | $1,160 |
| Hydroxyurea | 22 | $648 |
| Megestrol Acetate | 12 | $486 |
| Prednisone | 27 | $223 |
| Ondansetron Hcl | 14 | $133 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi | $904 | $894,78161 claims |
| BayerNubeqa | $67,246 | $496,42437 claims |
| Sumitomo Pharma America, Inc.Orgovyx | $265 | $258,71998 claims |
| Exelixis Inc.Cabometyx | $910 | $243,99015 claims |
| AbbVieLupron Depot | $267 | $42,77311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Tustin
- Joel NeutelTustin$34.9M
- Andrew ChengSouth San Francisco$55.1M
- Donald BrandonSan Diego$34M
- William TownerLos Angeles$27.4M
- Rahul AggarwalSan Francisco$24M
- Masoud AzizadNorthridge$21.1M
- Helen StaceyWalnut Creek$20.4M
- Rohit Loombala Jolla$15.1M
- Zeid KayaliColton$14.2M
- Alexandra DrakakiSanta Monica$14.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.